首页> 外文期刊>Stem Cell Research & Therapy >Platelet lysate as a novel serum-free media supplement for the culture of equine bone marrow-derived mesenchymal stem cells
【24h】

Platelet lysate as a novel serum-free media supplement for the culture of equine bone marrow-derived mesenchymal stem cells

机译:血小板裂解物作为一种新型无血清培养基,用于培养马骨髓间充质干细胞

获取原文
       

摘要

Mesenchymal stem cells (MSCs) produced for clinical purposes rely on culture media containing fetal bovine serum (FBS) which is xenogeneic and has the potential to significantly alter the MSC phenotype, rendering these cells immunogenic. As a result of bovine-derived exogenous proteins expressed on the cell surface, MSCs may be recognized by the host immune system as non-self and be rejected. Platelet lysate (PL) may obviate some of these concerns and shows promising results in human medicine as a possible alternative to FBS. Our goal was to evaluate the use of equine platelet lysate (ePL) pooled from donor horses in place of FBS to culture equine MSCs. We hypothesized that ePL, produced following apheresis, will function as the sole media supplement to accelerate the expansion of equine bone marrow-derived MSCs without altering their phenotype and their immunomodulatory capacity. Platelet concentrate was obtained via plateletpheresis and ePL were produced via freeze-thaw and centrifugation cycles. Population doublings (PD) and doubling time (DT) of bone marrow-derived MSCs (n = 3) cultured with FBS or ePL media were calculated. Cell viability, immunophenotypic analysis, and trilineage differentiation capacity of MSCs were assessed accordingly. To assess the ability of MSCs to modulate inflammatory responses, E. coli lipopolysaccharide (LPS)-stimulated monocytes were cocultured with MSCs cultured in the two different media formulations, and cell culture supernatants were assayed for the production of tumor necrosis factor (TNF)-α. Our results showed that MSCs cultured in ePL media exhibited similar proliferation rates (PD and DT) compared with those cultured in FBS at individual time points. MSCs cultured in ePL showed a statistically significant increased viability following a single washing step, expressed similar levels of MSC markers compared to FBS, and were able to differentiate towards the three lineages. Finally, MSCs cultured in ePL efficiently suppressed the release of TNF-α when exposed to LPS-stimulated monocytes similar to those cultured in FBS. ePL has the potential to be used for the expansion of MSCs before clinical application, avoiding the concerns associated with the use of FBS.
机译:为临床目的而生产的间充质干细胞(MSC)依赖于含有胎牛血清(FBS)的培养基,胎牛血清是异种的,并且具有显着改变MSC表型的潜力,从而使这些细胞具有免疫原性。作为牛源性外源蛋白在细胞表面表达的结果,MSC可能被宿主免疫系统识别为非自身的并被排斥。血小板裂解液(PL)可以消除其中的一些问题,并在人类医学中显示出有望成为FBS替代品的前景。我们的目标是评估使用从供体马那里收集的马血小板裂解液(ePL)代替FBS来培养马MSC。我们假设单采血液分离术产生的ePL将充当唯一的介质补充剂,以加速马骨髓来源的MSC的扩增,而不会改变其表型和免疫调节能力。血小板浓缩物通过血小板分离获得,而ePL则通过冻融和离心循环产生。计算了用FBS或ePL培养基培养的骨髓间充质干细胞(n = 3)的群体倍增(PD)和倍增时间(DT)。相应地评估了MSC的细胞活力,免疫表型分析和三系分化能力。为了评估MSC调节炎症反应的能力,将大肠杆菌脂多糖(LPS)刺激的单核细胞与在两种不同培养基配方中培养的MSC共培养,并分析细胞培养上清液中肿瘤坏死因子(TNF)-的产生。 α。我们的结果表明,与在单个时间点在FBS中培养的MSC相比,在ePL培养基中培养的MSC表现出相似的增殖速率(PD和DT)。在ePL中培养的MSC在单个洗涤步骤后显示出统计学上显着提高的生存力,与FBS相比表达了相似水平的MSC标记,并且能够向这三个谱系分化。最后,在ePL中培养的MSC暴露于LPS刺激的单核细胞(类似于在FBS中培养的那些)时,可有效抑制TNF-α的释放。 ePL有潜力在临床应用之前用于MSC的扩展,从而避免了与FBS使用相关的担忧。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号